KDNY - Chinook Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.345B

Cash

350.4M

Avg Qtr Burn

-35.86M

Short % of Float

7.61%

Insider Ownership

2.61%

Institutional Own.

96.29%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Atrasentan Details Kidney disease, Glomerular diseases, IgA nephropathy Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atrasentan Details Glomerular diseases, Kidney disease	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BION-1301 (Zigakibart) Details IgA nephropathy	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CHK-336 Details Primary hyperoxaluria	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.